Lantern Pharma wins USPTO notice of allowance for LP-284 blood cancer treatment patent application
Bitget2026/09/22 11:45- Lantern Pharma received a USPTO Notice of Allowance for a method-of-treatment patent covering LP-284 in mantle cell lymphoma, double-hit lymphoma.
- Claims include LP-284 as monotherapy or in combinations with other anti-cancer agents, with intravenous or intraperitoneal administration covered.
- Once issued, the patent is expected to extend LP-284 protection into 2042, adding to composition-of-matter coverage into 2039.
- LP-284 is in a Phase 1a dose-escalation trial in relapsed or refractory B-cell non-Hodgkin’s lymphomas, solid tumors.
- Lantern cited a $4 billion annual global market opportunity for targeted blood cancers, estimating 40,000 to 80,000 patients annually.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citi optimistic about international oil companies: low-cost resource reserves being rebuilt may drive energy sector to reverse a decade-long valuation discount
With oil prices in the mid-$70s range, Citi believes that global international oil companies (IOCs) can deliver a free cash flow yield of 7% to 8%, and achieve a real growth rate of 4% to 5% over a period of time.
Honda Motor (HMC.US) Reports 65.7% Increase in Net Profit in the First Half, Plans to Expand Production Capacity in North America and Brazil
Honda Motor (HMC.US) released its financial results for the first half of fiscal year 2027 on November 10.
Crypto winter not over? Mining rig hosting provider Bitari cancels orders at the last minute, IPO plans put on hold
Bitcoin mining service provider Bitari has withdrawn its Nasdaq IPO plan. The company originally intended to issue 4.3 million shares at $7 per share to raise $30 million. Its annual revenue is approximately $11 million.
Crypto prices
More
